Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Genomics

Background:

• Triple negative breast cancer (TNBC) has a high mortality rate and lacks FDA-approved targeted therapies.
• Genomic analyses reveal PI3K-pathway activation in most TNBC cases.
• Single-agent therapies often face resistance, necessitating combination approaches targeting compensatory pathways.

Purpose of the Study:

• To identify novel targeted therapies for TNBC through genomic analysis.
• To investigate combination therapy targeting the PI3K and Wnt pathways in TNBC.
• To evaluate the synergistic efficacy of dual PI3K and Wnt pathway inhibition.

Main Methods:

• Genomic-guided analysis to identify therapeutic targets in TNBC.
• In vitro and in vivo studies using specific inhibitors: buparlisib (pan-PI3K inhibitor) and WNT974 (Wnt-pathway inhibitor).
• Assessment of synergistic effects of combined drug treatment on TNBC cell lines and xenografts.

Main Results:

• Pan-PI3K inhibition leads to significant activation of the Wnt-pathway in TNBC.
• Combination therapy with buparlisib and WNT974 demonstrated significant in vitro and in vivo synergy.
• Effective suppression of TNBC cell lines and xenografts was observed with the combination treatment.

Conclusions:

• Dual targeting of the PI3K and Wnt pathways presents a potent therapeutic strategy for TNBC.
• The combination of buparlisib and WNT974 shows strong preclinical evidence for clinical application.
• Further clinical trials are warranted to validate this dual-targeting approach in TNBC patients.